Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome

Oraee‐Yazdani, Saeed; Hafizi, Maryam; Atashi, Amir; Ashrafi, Farzad; Seddighi, AS; Hashemi, Seyed Mahmoud; Seddighi, Afsoun; Soleimani, Masoud; Zali, Alireza

doi:10.1038/sc.2015.142

Cited by 73 publications

(47 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different procedures have been reported, including intravenous, intramedullary and intradural transplantations [38,[58][59][60] . Following systemic and parenchymal transplantation, the limited number and viability of stem cells in situ and pulmonary passage impede the effectiveness of this technique [61,62] .…”

Section: Discussionmentioning

confidence: 99%

“…Following systemic and parenchymal transplantation, the limited number and viability of stem cells in situ and pulmonary passage impede the effectiveness of this technique [61,62] . Oraee-Yazdani et al reported a co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid (CSF) for the treatment of patients with chronic spinal cord injury [58] . During follow-up, which lasted an average of 30 months, no evidence of neoplastic tissue overgrowth was identified via magnetic resonance imaging.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multichannel polymer scaffold seeded with activated Schwann cells and bone mesenchymal stem cells improves axonal regeneration and functional recovery after rat spinal cord injury

Yang

Zhang

et al. 2017

Acta Pharmacol Sin

View full text Add to dashboard Cite

The adult mammalian CNS has a limited capacity to regenerate after traumatic injury. In this study, a combinatorial strategy to promote axonal regeneration and functional recovery after spinal cord injury (SCI) was evaluated in adult rats. The rats were subjected to a complete transection in the thoracic spinal cord, and multichannel scaffolds seeded with activated Schwann cells (ASCs) and/or rat bone marrow-derived mesenchymal stem cells (MSCs) were acutely grafted into the 3-mm-wide transection gap. At 4 weeks posttransplantation and thereafter, the rats receiving scaffolds seeded with ASCs and MSCs exhibited significant recovery of nerve function as shown by the Basso, Beattie and Bresnahan (BBB) score and electrophysiological test results. Immunohistochemical analyses at 4 and 8 weeks after transplantation revealed that the implanted MSCs at the lesion/graft site survived and differentiated into neuron-like cells and co-localized with host neurons. Robust bundles of regenerated fibers were identified in the lesion/graft site in the ASC and MSC co-transplantation rats, and neurofilament 200 (NF) staining confirmed that these fibers were axons. Furthermore, myelin basic protein (MBP)-positive myelin sheaths were also identified at the lesion/graft site and confirmed via electron microscopy. In addition to expressing mature neuronal markers, sparse MSC-derived neuron-like cells expressed choline acetyltransferase (ChAT) at the injury site of the ASC and MSC co-transplantation rats. These findings suggest that co-transplantation of ASCs and MSCs in a multichannel polymer scaffold may represent a novel combinatorial strategy for the treatment of spinal cord injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Multichannel polymer scaffold seeded with activated Schwann cells and bone mesenchymal stem cells improves axonal regeneration and functional recovery after rat spinal cord injury

Yang

Zhang

et al. 2017

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…Partial functions and the quality of life have been improved following transplantation of cells into cord parenchyma, intrathecal administration of cells (lesion area or lumbar subarachnoid space), intravascular infusion of cells, and by multiple routes of administration. 11,[58][59][60][61][62][63][64][65][66][67][68] Increasing studies have showed that extracellular vesicles such as exosomes have recently been suggested to mediate neurorestorative effects, [69][70][71] and may offer a possible alternative therapeutic strategy for SCI in future.…”

Section: Cell Therapymentioning

confidence: 99%

Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016)

Feng¹,

Sun²,

Chen³

et al. 2017

View full text Add to dashboard Cite

Abstract:Restoring functions following spinal cord injury (SCI) was the most challenging task in clinical practice in the past. Fortunately, some effective neurorestorative methods have been exploited in acute, subacute, and chronic phase of SCI. There were no clinical neurorestorative therapeutic guidelines available before this document which can be followed by physicians to manage patients with acute, subacute, and chronic SCI. This guideline will be a helpful reference to physicians to implement their neurorestorative strategies that can help to improve the neurological functions in patients with SCI and their quality of life.

show abstract

“…One of these is gelation properties that must be compatible with the injection conditions necessary to avoid additional injury to the cord tissue: a syringe capable of delivering small volumes at a controlled rate equipped with a small needle. Specific sizes depend upon the injury model used, with needles as small as 33 G used for rodent studies [Gupta et al, 2006;Sontag et al, 2014;Führmann et al, 2015], and needles up to as large as 23 G used in human clinical trials [Oraee-Yazdani et al, 2016;Shin et al, 2015]. These requirements dictate that the precursor must be liquid or highly deformable.…”

Section: Design Considerations For Hydrogels Promoting Sci Repairmentioning

confidence: 99%

“…There are, however, common accepted standards for volumes of 1-2 μl of cell solutions or hydrogels injected per site into the mouse cord [Shin et al, 2015;Oraee-Yazdani et al, 2016] or 5-10 μl in the rat spinal cord [Yang et al, 2009a;Lu et al, 2012;Song et al, 2012;Führmann et al, 2015]. Complicating the situation, the acceptable range for injection volumes is likely to be specific to the unique swelling properties of each hydrogel formulation.…”

Section: Design Considerations For Hydrogels Promoting Sci Repairmentioning

confidence: 99%

Injectable Hydrogels for Spinal Cord Repair: A Focus on Swelling and Intraspinal Pressure

Khaing

Ehsanipour

Hofstetter

et al. 2016

Cells Tissues Organs

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a devastating condition that leaves patients with limited motor and sensory function at and below the injury site, with little to no hope of a meaningful recovery. Because of their ability to mimic multiple features of central nervous system (CNS) tissues, injectable hydrogels are being developed that can participate as therapeutic agents in reducing secondary injury and in the regeneration of spinal cord tissue. Injectable biomaterials can provide a supportive substrate for tissue regeneration, deliver therapeutic factors, and regulate local tissue physiology. Recent reports of increasing intraspinal pressure after SCI suggest that this physiological change can contribute to injury expansion, also known as secondary injury. Hydrogels contain high water content similar to native tissue, and many hydrogels absorb water and swell after formation. In the case of injectable hydrogels for the spinal cord, this process often occurs in or around the spinal cord tissue, and thus may affect intraspinal pressure. In the future, predictable swelling properties of hydrogels may be leveraged to control intraspinal pressure after injury. Here, we review the physiology of SCI, with special attention to the current clinical and experimental literature, underscoring the importance of controlling intraspinal pressure after SCI. We then discuss how hydrogel fabrication, injection, and swelling can impact intraspinal pressure in the context of developing injectable biomaterials for SCI treatment.

show abstract

Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome

Cited by 73 publications

References 26 publications

Multichannel polymer scaffold seeded with activated Schwann cells and bone mesenchymal stem cells improves axonal regeneration and functional recovery after rat spinal cord injury

Multichannel polymer scaffold seeded with activated Schwann cells and bone mesenchymal stem cells improves axonal regeneration and functional recovery after rat spinal cord injury

Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016)

Injectable Hydrogels for Spinal Cord Repair: A Focus on Swelling and Intraspinal Pressure

Contact Info

Product

Resources

About